| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Air pollution linked to lung cancer
|
|
|
|
10 |
5 |
p. 485-486
|
artikel
|
| 2 |
Anaphylaxis after oxaliplatin
|
Médioni, J.
|
|
|
10 |
5 |
p. 610
|
artikel
|
| 3 |
Anaphylaxis after oxaliplatin
|
J. Médioni
|
|
1999
|
10 |
5 |
p. 610-610
1 p.
|
artikel
|
| 4 |
A new approach to safeguard high standards and cost containment of stem cell transplantation in Germany
|
Diehl, V.
|
|
|
10 |
5 |
p. 609
|
artikel
|
| 5 |
A new approach to safeguard high standards and cost containment of stem cell transplantation in Germany
|
V. Diehl
|
|
1999
|
10 |
5 |
p. 609-609
1 p.
|
artikel
|
| 6 |
Anthracyclines in non-small-cell lung cancer: Do they have a therapeuticrole?
|
A. Martoni
|
|
1999
|
10 |
5 |
p. 19-23
5 p.
|
artikel
|
| 7 |
Antisense - time to shoot the messenger
|
Kuss, B.
|
|
|
10 |
5 |
p. 495-504
|
artikel
|
| 8 |
Antisense time to shoot the messenger
|
B. Kuss
|
|
1999
|
10 |
5 |
p. 495-503
9 p.
|
artikel
|
| 9 |
At home management of aplastic phase following high-dose chemotherapy with stem-cell rescue for hematological and non-hematological malignancies
|
Westermann, A.M.
|
|
|
10 |
5 |
p. 511-518
|
artikel
|
| 10 |
At home management of aplastic phase following high-dose chemotherapy with stem-cell rescue for hematological and non-hematological malignancies
|
A. M. Westermann
|
|
1999
|
10 |
5 |
p. 511-517
7 p.
|
artikel
|
| 11 |
Awards, apointments
|
|
|
|
10 |
5 |
p. 487
|
artikel
|
| 12 |
Book review
|
Obrist, R.
|
|
|
10 |
5 |
p. 592
|
artikel
|
| 13 |
Book review
|
Fey, M.
|
|
|
10 |
5 |
p. 604
|
artikel
|
| 14 |
Book review
|
Ghielmini, M.
|
|
|
10 |
5 |
p. 492
|
artikel
|
| 15 |
Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma
|
Przepiorka, D.
|
|
|
10 |
5 |
p. 527-529
|
artikel
|
| 16 |
Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma
|
D. Przepiorka
|
|
1999
|
10 |
5 |
p. 527-532
6 p.
|
artikel
|
| 17 |
Chemoradiotherapy interactions and lung toxicity
|
K.-R. Trott
|
|
1999
|
10 |
5 |
p. 75-79
5 p.
|
artikel
|
| 18 |
Chemotherapy in carcinomas of unknown primary site: A high-dose intensity policy
|
Culine, S.
|
|
|
10 |
5 |
p. 569-576
|
artikel
|
| 19 |
Chemotherapy in carcinomas of unknown primary site: A high-dose intensity policy
|
S. Culine
|
|
1999
|
10 |
5 |
p. 569-575
7 p.
|
artikel
|
| 20 |
Chemotherapy of non-small-cell lung cancer: Role of erythropoietin in the management of anemia
|
L. Del Mastro
|
|
1999
|
10 |
5 |
p. 89-92
4 p.
|
artikel
|
| 21 |
Cisplatin and gemcitabine in non-small-cell lung cancer
|
G. Cartei
|
|
1999
|
10 |
5 |
p. 57-62
6 p.
|
artikel
|
| 22 |
Contents of the next issue
|
|
|
|
10 |
5 |
p. vi
|
artikel
|
| 23 |
Copyright
|
|
|
|
10 |
5 |
p. iv
|
artikel
|
| 24 |
Disappointment over ABMT in breast cancer, gratification at neoadjuvant therapy in cervical cancer
|
|
|
|
10 |
5 |
p. 485
|
artikel
|
| 25 |
Disappointment over ABMT in breast cancer, gratification at neoadjuvant therapy in cervical cancer; Air pollution linked to lung cancer; Money from stamps, but not from industry; IELSG activity expands; Awards, appointments; Reply to a News: Oncology in Italy: The role of state hospitals is still predominant; Who wants to participate to the IELSG trials of extranodal lymphomas?; Perhaps not everyone knows that...
|
|
|
1999
|
10 |
5 |
p. 485-491
7 p.
|
artikel
|
| 26 |
Docetaxel (Taxotere®) in combination chemotherapy and in associationwith thoracic radiotherapy for the treatment of non-small-cell lungcancer
|
D. L. Ornstein
|
|
1999
|
10 |
5 |
p. 35-40
6 p.
|
artikel
|
| 27 |
Docetaxel (Taxotere®) in the neo-adjuvant setting in non-small-cell lung cancer
|
K. Mattson
|
|
1999
|
10 |
5 |
p. 67-70
4 p.
|
artikel
|
| 28 |
Dose-escalation of CHOP in non-Hodgkin's lymphoma
|
Santoro, A.
|
|
|
10 |
5 |
p. 519-526
|
artikel
|
| 29 |
Dose-escalation of CHOP in non-Hodgkins lymphoma
|
A. Santoro
|
|
1999
|
10 |
5 |
p. 519-525
7 p.
|
artikel
|
| 30 |
Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer
|
Misset, J.L.
|
|
|
10 |
5 |
p. 553-560
|
artikel
|
| 31 |
Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer
|
J. L. Misset
|
|
1999
|
10 |
5 |
p. 553-560
8 p.
|
artikel
|
| 32 |
Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer
|
Pagani, O.
|
|
|
10 |
5 |
p. 539-546
|
artikel
|
| 33 |
Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer
|
O. Pagani
|
|
1999
|
10 |
5 |
p. 539-545
7 p.
|
artikel
|
| 34 |
D. W. Ross.; Introduction to oncogenes and molecular cancer medicine
|
M. Fey
|
|
1999
|
10 |
5 |
p. 604-604
1 p.
|
artikel
|
| 35 |
Editorial
|
G. Cartei
|
|
1999
|
10 |
5 |
p. 1-1
1 p.
|
artikel
|
| 36 |
Editorial Board
|
|
|
|
10 |
5 |
p. v
|
artikel
|
| 37 |
E. E. Vokes, H. M. Golomb (eds).; Oncologic therapies
|
M. Ghielmini
|
|
1999
|
10 |
5 |
p. 492-492
1 p.
|
artikel
|
| 38 |
ESHAP is an active regimen for relapsing Hodgkin's disease
|
Aparicio, J.
|
|
|
10 |
5 |
p. 593-595
|
artikel
|
| 39 |
ESHAP is an active regimen for relapsing Hodgkins disease
|
J. Aparicio
|
|
1999
|
10 |
5 |
p. 593-595
3 p.
|
artikel
|
| 40 |
Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: A multicenter dose-escalation study
|
Kouroussis, C.
|
|
|
10 |
5 |
p. 547-552
|
artikel
|
| 41 |
Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: A multicenter dose-escalation study
|
C. Kouroussis
|
|
1999
|
10 |
5 |
p. 547-552
6 p.
|
artikel
|
| 42 |
Gemcitabine: A real major advance?
|
Roila, F.
|
|
|
10 |
5 |
p. 609-610
|
artikel
|
| 43 |
Gemcitabine: A real major advance?
|
F. Roila
|
|
1999
|
10 |
5 |
p. 609-610
2 p.
|
artikel
|
| 44 |
High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234
|
Vogelzang, N.J.
|
|
|
10 |
5 |
p. 597-600
|
artikel
|
| 45 |
High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234
|
N. J. Vogelzang
|
|
1999
|
10 |
5 |
p. 597-600
4 p.
|
artikel
|
| 46 |
IELSG Activity expands
|
|
|
|
10 |
5 |
p. 486-487
|
artikel
|
| 47 |
Ifosfamide in non-small-cell lung cancer
|
R. Rosell
|
|
1999
|
10 |
5 |
p. 25-28
4 p.
|
artikel
|
| 48 |
In this issue
|
|
|
|
10 |
5 |
p. vi
|
artikel
|
| 49 |
L. Balducci, G. H. Lyman, W. B. Ershler (eds).; Comprehensive geriatric oncology
|
R. Obrist
|
|
1999
|
10 |
5 |
p. 592-592
1 p.
|
artikel
|
| 50 |
Molecular epidemiology of lung cancer
|
P. G. Shields
|
|
1999
|
10 |
5 |
p. 7-11
5 p.
|
artikel
|
| 51 |
Money from stamps, but not from industry
|
|
|
|
10 |
5 |
p. 486
|
artikel
|
| 52 |
Multidrug resistance in non-small-cell lung cancer
|
G. V. Scagliotti
|
|
1999
|
10 |
5 |
p. 81-84
4 p.
|
artikel
|
| 53 |
Paclitaxel-based therapy in non-small-cell lung cancer: Improved thirdgeneration chemotherapy
|
F. A. Greco
|
|
1999
|
10 |
5 |
p. 63-66
4 p.
|
artikel
|
| 54 |
Perhaps not everyone knows that…
|
|
|
|
10 |
5 |
p. 489-491
|
artikel
|
| 55 |
Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation in patients with refractory or relapsed acute leukemia
|
Vey, N.
|
|
|
10 |
5 |
p. 577-584
|
artikel
|
| 56 |
Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation in patients with refractory or relapsed acute leukemia
|
N. Vey
|
|
1999
|
10 |
5 |
p. 577-583
7 p.
|
artikel
|
| 57 |
Phase I study of the sequential administration of edatrexate and paclitaxel in patients with advanced solid tumors
|
Rigas, J.R.
|
|
|
10 |
5 |
p. 601-603
|
artikel
|
| 58 |
Phase I study of the sequential administration of edatrexate and paclitaxel in patients with advanced solid tumors
|
J. R. Rigas
|
|
1999
|
10 |
5 |
p. 601-603
3 p.
|
artikel
|
| 59 |
Redefining the therapeutic goals in chronic lymphocytic leukemia: Towards an evidence-based, risk-adapted therapy*
|
Wendtner, C.M.
|
|
|
10 |
5 |
p. 505-510
|
artikel
|
| 60 |
Redefining the therapeutic goals in chronic lymphocytic leukemia: Towards an evidence-based, risk-adapted therapy
|
C. M. Wendtner
|
|
1999
|
10 |
5 |
p. 505-509
5 p.
|
artikel
|
| 61 |
Reply to a ‘News’: Oncology in ltaly: The role of state hospitals is still predominant
|
|
|
|
10 |
5 |
p. 487-488
|
artikel
|
| 62 |
Retinoids in lung cancer chemoprevention and treatment
|
S. Toma
|
|
1999
|
10 |
5 |
p. 93-100
8 p.
|
artikel
|
| 63 |
Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 107 patients with non-small-cell lung cancer: A mature follow-up report
|
Fetscher, S.
|
|
|
10 |
5 |
p. 605-608
|
artikel
|
| 64 |
Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 107 patients with non-small-cell lung cancer: A mature follow-up report
|
S. Fetscher
|
|
1999
|
10 |
5 |
p. 605-607
3 p.
|
artikel
|
| 65 |
Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 100 patients with small-cell lung cancer: A mature follow-up report
|
Fetscher, S.
|
|
|
10 |
5 |
p. 561-568
|
artikel
|
| 66 |
Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 100 patients with small-cell lung cancer: A mature follow-up report
|
S. Fetscher
|
|
1999
|
10 |
5 |
p. 561-567
7 p.
|
artikel
|
| 67 |
Stem cell transplant at home: Glimpse of the future
|
Reed, E.
|
|
|
10 |
5 |
p. 493-494
|
artikel
|
| 68 |
Stem cell transplant at home: Glimpse of the future
|
E. Reed
|
|
1999
|
10 |
5 |
p. 493-494
2 p.
|
artikel
|
| 69 |
Synchronous inflammatory breast cancer and advanced ovarian carcinoma: A case with prolonged disease-free survival*
|
Sandor, V.
|
|
|
10 |
5 |
p. 585-588
|
artikel
|
| 70 |
Synchronous inflammatory breast cancer and advanced ovarian carcinoma: A case with prolonged disease-free survival
|
V. Sandor
|
|
1999
|
10 |
5 |
p. 585-588
4 p.
|
artikel
|
| 71 |
Table of Contents
|
|
|
|
10 |
5 |
p. iii-iv
|
artikel
|
| 72 |
The combination of etoposide and cisplatin in non-small-cell lung cancer(NSCLC)
|
A. Ardizzoni
|
|
1999
|
10 |
5 |
p. 13-17
5 p.
|
artikel
|
| 73 |
The epidemiology of lung cancer
|
S. Franceschi
|
|
1999
|
10 |
5 |
p. 3-6
4 p.
|
artikel
|
| 74 |
The high-dose sequential (Milan) chemotherapy/PBSC transplantation regimen for patients with lymphoma is not cardiotoxic
|
Ghielmini, M.
|
|
|
10 |
5 |
p. 534-538
|
artikel
|
| 75 |
The high-dose sequential (Milan) chemotherapy/PBSC transplantation regimen for patients with lymphoma is not cardiotoxic
|
M. Ghielmini
|
|
1999
|
10 |
5 |
p. 533-537
5 p.
|
artikel
|
| 76 |
The metalloproteinase inhibitor batimastat (BB-94) causes cell cycle phase perturbations in ovarian cancer cells
|
Erba, E.
|
|
|
10 |
5 |
p. 589-591
|
artikel
|
| 77 |
The metalloproteinase inhibitor batimastat (BB-94) causes cell cycle phase perturbations in ovarian cancer cells
|
E. Erba
|
|
1999
|
10 |
5 |
p. 589-591
3 p.
|
artikel
|
| 78 |
Therapy of non-small-cell lung cancer (NSCLC) in patients with HIVinfection
|
M. Spina
|
|
1999
|
10 |
5 |
p. 85-88
4 p.
|
artikel
|
| 79 |
The role of single-agent gemcitabine in the treatment of non-small-celllung cancer
|
K. Kelly
|
|
1999
|
10 |
5 |
p. 53-55
3 p.
|
artikel
|
| 80 |
The role of surgery in integrated therapies for non-small-cell lungcancer
|
F. Sartori
|
|
1999
|
10 |
5 |
p. 71-74
4 p.
|
artikel
|
| 81 |
This letter was referred to the authors, who respond as follows
|
A. Thomas
|
|
1999
|
10 |
5 |
p. 610-610
1 p.
|
artikel
|
| 82 |
Tirapazamine: A new drug producing tumor specific enhancement ofplatinum-based chemotherapy in non-small-cell lung cancer
|
B. G. Wouters
|
|
1999
|
10 |
5 |
p. 29-33
5 p.
|
artikel
|
| 83 |
Vinorelbine (Navelbine®) in the treatment of non-small-cell lungcancer: Recent developments in combination chemotherapy and radiotherapy
|
R. Gralla
|
|
1999
|
10 |
5 |
p. 47-51
5 p.
|
artikel
|
| 84 |
Vinorelbine (Navelbine®) in the treatment of non-small-cell lungcancer: Studies with single-agent therapy and in combination withcisplatin
|
R. Gralla
|
|
1999
|
10 |
5 |
p. 41-45
5 p.
|
artikel
|
| 85 |
Who wants to participate in the IELSG trials of extranodal lymphomas?
|
|
|
|
10 |
5 |
p. 488
|
artikel
|
Tijdschrift beschrijving